Sepr Xopenex news.. Huge
Second paragraph. 1.1 billion
2006 MAY 25 - (NewsRx.com) -- Decision Resources, Inc., a research and advisory firm focusing on pharmaceutical and health care issues, finds that compliance to a clean air treaty by the United States Food and Drug Administration (FDA) will force leading metered-dose inhalers containing ozone-depleting propellants off the U.S. asthma treatment market by the end of 2008. "Because all current generic versions of inhaled albuterol contain ozone-depleting chlorofluorocarbon (CFC) propellants, all generics will be removed from the U.S. market in 2008, leaving only higher-priced branded albuterol propelled with hydrofluoroalkane," said Vickie Lai, analyst at Decision Resources. "As a result, the albuterol market in the U.S. will become branded only, leading to $1 billion in major market sales for Ventolin and Proventil in 2014-more than doubling their sales totals from 2004."
The report also finds that more physicians will turn to levalbuterol as an alternative to albuterol, generating $1.1 billion in sales in the seven major markets for Sepracor's Xopenex (levalbuterol) in 2014.
"Because all current generic versions of inhaled albuterol contain ozone-depleting chlorofluorocarbon (CFC) propellants, all generics will be removed from the U.S. market in 2008, leaving only higher-priced branded albuterol propelled with hydrofluoroalkane," said Vickie Lai, analyst at Decision Resources. "As a result, the albuterol market in the U.S. will become branded only, leading to $1 billion in major market sales for Ventolin and Proventil in 2014-more than doubling their sales totals from 2004."
2006 MAY 25 - (NewsRx.com) -- Decision Resources, Inc., a research and advisory firm focusing on pharmaceutical and health care issues, finds that compliance to a clean air treaty by the United States Food and Drug Administration (FDA) will force leading metered-dose inhalers containing ozone-depleting propellants off the U.S. asthma treatment market by the end of 2008. "Because all current generic versions of inhaled albuterol contain ozone-depleting chlorofluorocarbon (CFC) propellants, all generics will be removed from the U.S. market in 2008, leaving only higher-priced branded albuterol propelled with hydrofluoroalkane," said Vickie Lai, analyst at Decision Resources. "As a result, the albuterol market in the U.S. will become branded only, leading to $1 billion in major market sales for Ventolin and Proventil in 2014-more than doubling their sales totals from 2004."
The report also finds that more physicians will turn to levalbuterol as an alternative to albuterol, generating $1.1 billion in sales in the seven major markets for Sepracor's Xopenex (levalbuterol) in 2014.
"Because all current generic versions of inhaled albuterol contain ozone-depleting chlorofluorocarbon (CFC) propellants, all generics will be removed from the U.S. market in 2008, leaving only higher-priced branded albuterol propelled with hydrofluoroalkane," said Vickie Lai, analyst at Decision Resources. "As a result, the albuterol market in the U.S. will become branded only, leading to $1 billion in major market sales for Ventolin and Proventil in 2014-more than doubling their sales totals from 2004."
posted by JV at 7:22 PM
<< Home